Mr. Shi lichen: there are five models for the transformation of pharmaceutical enterprises to biopharmaceuticals

[expert opinion of China Pharmaceutical network] biopharmaceutical is a method of using living organisms to produce drugs It is an industry with large investment, long cycle and high R & D risk When chemical and general pharmaceutical enterprises are transforming into Biopharmaceutical Enterprises, they need to identify the risks of biopharmaceutical business units, so pharmaceutical enterprises can adopt five models (Shi lichen: there are five models for pharmaceutical companies to transform to biopharmaceutical products Picture source: Baidu pictures) (I) cooperate with laboratories or research institutes to develop biopharmaceutical products Because the R & D of biopharmaceutical products needs high-level professional talents, and chemical and general pharmaceutical enterprises just transform to biopharmaceutical products, they do not have biological R & D talents, and there are not many talents in the field of biological R & D in China, so the cooperation with laboratories or research institutes to develop biopharmaceutical products can avoid the transformation failure due to the lack of talents At the same time, laboratories or research institutes have better biological R & D equipment, which also avoids the large amount of money spent on R & D equipment in the early stage of drug enterprise transformation In addition, some laboratories or research institutes have their own research and development achievements in the field of biopharmaceutical research and development, and even some laboratories or research institutes have relevant achievements, but these have not yet been converted into specific biopharmaceutical The cooperation between chemical medicine and general medicine enterprises and laboratories or research institutes can shorten the transformation time to biopharmaceutical by virtue of their talents, equipment and existing R & D technology, as well as save a large number of funds (II) joint research and development of biological drugs with multinational companies Now, the research and development of large-scale domestic pharmaceutical enterprises in the field of biological drugs is docking with international multinational enterprises, that is, the internationalization of the research and development mode of biological products of pharmaceutical enterprises, from the original internal oriented research and development organization to the open multi-channel cooperative research and development mode Experts from Beijing Dingchen medical management consulting center believe that the integration of market-oriented, clinical compliant R & D organization and open market-oriented R & D will be the key to the rapid transformation of Chinese pharmaceutical enterprises into the field of biopharmaceutical For example, Xiansheng Pharmaceutical Co., Ltd and Bristol Myers Squibb jointly developed the anti-tumor drug bms-817378, Tianshili and French merier development alliance jointly established the biomedical research company, Lizhu group and jiankangyuan established the McAb pharmaceutical platform, etc (3) through the division and cooperation of pharmaceutical enterprises and universities, the joint research and development of biopharmaceuticals with universities can quickly realize the transformation of product structure and the transformation of growth mode The choice of the first mock exam will break the thinking formula of "two high and one long" for new drug research and development "Through the division and cooperation of the function chain and interest chain of production, learning and research, the time and funds originally invested by an enterprise or institution are decomposed in each link of production, learning and research On the premise of ensuring quality, for a single functional chain, the burden of time and cost will not be very heavy, but the results of mass production can be shared at the same time, and there is hope to achieve win-win and multi win " Peace said Experts from Beijing Dingchen pharmaceutical management consulting center said that cooperation between pharmaceutical companies and universities in drug research and development has become the norm, not limited to the field of biopharmaceutics For example, Huiyuan Biotechnology Co., Ltd has reached a strategic cooperation agreement with the Interdisciplinary Research Institute (miir) of Marshall University and Joan C Edwards Medical College in the United States to jointly carry out the research and development of anti-tumor drugs and kidney disease drugs For example, Tsinghua University and Bayer healthcare Co., Ltd jointly signed a new strategic cooperation agreement, expanded the research work of "Tsinghua Bayer Joint Research Center for innovative drugs" project, and carried out research cooperation in the biomedical field For example, leap soil, a leading enterprise in the dye industry in China, started to cross the border and signed a cooperation agreement on research and development of innovative drug technology with the first class group of Yale University in the United States to cooperate in the research of tumor molecular projects (4) small biotech companies investing in small and reliable biotech companies are generally founded by returned professional R & D personnel with biotech These professional R & D personnel have very advanced R & D technology for related drugs in the field of biopharmaceutical in foreign pharmaceutical companies, research labs or universities, and even some professionals have their own R & D achievements in the field of biopharmaceutical Experts from Beijing Dingchen medical management consulting center believe that when general medicine and chemical medicine enterprises are transforming into Biopharmaceutical Enterprises, they can enter the field of biopharmaceutical more quickly with the talents, equipment and research and development achievements of these small biotechnology companies In general, these small biotech companies are very short of R & D funds and clinical R & D resources The cooperation between pharmaceutical companies and these small biotech companies is a win-win situation Moreover, because it is a small biotech company with a simple capital structure and a small share capital, a pharmaceutical enterprise can become a controlling shareholder or a major shareholder with a small amount of capital, then all the R & D achievements of this small biotech company will naturally become the achievements of the pharmaceutical enterprise in the future Of course, pharmaceutical companies should be very careful when investing in small biotech companies We must investigate the background of core R & D personnel of small companies Because there are many cheaters in the field of biology, some so-called professionals may not have any research and development technology or achievements at all, but they will cheat, talk big and understand terminology This makes some high-level pharmaceutical companies with weak discrimination easy to be trapped, which eventually leads to the failure of investment in pharmaceutical companies and, more seriously, the failure of transformation of pharmaceutical companies into biopharmaceuticals There are also many successful cases for pharmaceutical companies to invest in small biotechnology companies, such as the cooperation between Shanghai Pharmaceutical and Shanghai Fudan Zhangjiang biomedical Co., Ltd Shanghai Pharmaceutical and Shanghai Fudan Zhangjiang biopharmaceutical Co., Ltd signed a strategic cooperation agreement on the research and development of major new drugs In the next six years, SHP will invest 180 million yuan to cooperate with Shanghai Fudan Zhangjiang biomedical Co., Ltd in the research, development and industrialization of four drug varieties, including dotipofen, TNF receptor, vincristine sulfate liposome (lvcr) and recombinant human lymphotoxin α derivative (LT) With the opportunity of this cooperation, SHP has entered the three research and development fields of gene engineering, liposome and photodynamic, and improved the existing research and development system of SHP through professional research and development cooperation Shanghai Fudan Zhangjiang biopharmaceutical Co., Ltd focuses on the innovative research and development of biopharmaceuticals It is at the domestic advanced or level in the research and development of genetic engineering drugs, photodynamic drugs, liposome drugs and other fields Now a large number of drugs are at the key point of industrialization (V) establish innovation technology platform Innovation technology platform is to combine scientific research institutions, key laboratories and foreign biological research institutions to establish a new generation of cooperation platform for biopharmaceutical technology research, focus on breakthrough of target discovery technology, biotransformation technology and other new generation of biopharmaceutical technology, and vigorously develop biopharmaceuticals, new vaccines and diagnostic reagents with independent intellectual property rights and broad market prospects Using the platform to reduce the cost and risk of R & D, realize the sharing of innovative resources, shorten the R & D cycle and improve the development speed, and strive to occupy a place in the field of bio innovative drugs with development potential Experts from Beijing Dingchen medical management consulting center believe that the construction of innovative technology platform needs strong ability to integrate R & D resources and to utilize relevant national industrial policies The construction of innovation technology platform requires the background of large pharmaceutical enterprises or government, and small and medium-sized pharmaceutical enterprises cannot be established at all.